Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide - Summary - MDSpire

Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide

  • By

  • Silvia Cañizares

  • Laura Nuño

  • Pablo Barrio

  • Mireia Forner-Puntonet

  • Carolina Gavotti

  • Miquel Monràs

  • Patricia Gavín

  • Ricard Navinés

  • Lilliam Flores

  • Maite Barrios

  • Alba Andreu

  • Judit Molero

  • Amanda Jimenez

  • Josep Vidal

  • Anna Lligoña

  • March 12, 2025

  • 0 min

Share

Objective:

To assess the prevalence of risky drinking, alcohol use disorder (AUD), and other substance use in bariatric surgery (BS) candidates, and to compare these prevalences with those of the general Spanish population.

Key Findings:
  • 33% of participants met criteria for a current Axis I disorder, with major depressive disorder being the most common.
  • 4% of participants met criteria for alcohol abuse and 2% for dependence, with a higher prevalence in men.
  • 1% of participants met criteria for drug abuse and dependence.
  • 32% were prescribed antidepressants, 28% benzodiazepines, 17% opioids, and 5% antipsychotics.
Interpretation:

The study highlights a significant prevalence of risky drinking and mental health disorders among bariatric surgery candidates, indicating the need for thorough preoperative assessments to address these issues.

Limitations:
  • The study's sample size may limit the generalizability of the findings.
  • Self-reported data may be subject to bias, potentially affecting the accuracy of the prevalence rates.
Conclusion:

Preoperative screening for alcohol and substance use is crucial in bariatric surgery candidates to mitigate risks associated with surgery and postoperative outcomes.

Original Source(s)

Alcohol and Other Substance Screening in Bariatric Surgery Candidates: Utility of Self-Report and Toxicology Tests, Including Ethyl-Glucoronide

  • by Silvia Cañizares, Laura Nuño, Pablo Barrio, Mireia Forner-Puntonet, Carolina Gavotti, Miquel Monràs, Patricia Gavín, Ricard Navinés, Lilliam Flores, Maite Barrios, Alba Andreu, Judit Molero, Amanda Jimenez, Josep Vidal, Anna Lligoña

  • March 12, 2025

Related Content

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Half Avoid Opioids After Colorectal Surgery

Researchers examine postdischarge pain management after elective colorectal surgery, focusing on how prescribing practices align with actual opioid use at home.

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.